Papillary muscle scarring (papSCAR) is prevalent in one-third of DCM patients and predicts cardiac death independently. The FIDDLE technique significantly improves papSCAR detection sensitivity ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Papillary muscle scarring in DCM patients is associated with higher risks of cardiac death, heart failure, and arrhythmia events. Microvascular dysfunction is a strong predictor of poor prognosis, ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
TCT 1019: Complex degenerative mitral valve disease with a posterior cleft and severe regurgitation successfully treated using a single PASCAL Ace device with horizontal positioning. Receive the the ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Study honoraria to ...
The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results